|Description||FR 139317 is a selective Endothelin A receptor antagonist originated by Fujisawa. (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). No development was reported for the treatment of Cerebrovascular disorders, Coronary disorders, Diabetic nephropathies, Heart failure, Hypertension, Ischaemic heart disorders, Myocardial infarction and Renal failure.|
|Synonyms||PD 147953；2-((1-(Hexahydro-1H-azepinyl)carbonyl)amino-4-methylpentanoyl)-3-(-(1-methyl-1H-indolyl)propionyl)amino-3-(2-pyridyl)propionic acid|
|Solubility||Soluble in DMSO|
|Application||Cerebrovascular disorders; Coronary disorders; Diabetic nephropathies; Heart failure; Hypertension; Ischaemic heart disorders; Myocardial infarction; Renal failure|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Fujisawa|
Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.
A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmente...
BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.
Sitaxentan sodium inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.69 nM and a pA2 of 8.0.
SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.
Sitaxsentan, also called as IPI 1040 or TBC 11251, is a potent orally bioactive ET receptor antagonist that has a long duration of action (t1/2, 5–7 hours) and ...
RO462005 is an endothelin receptor selective agonist.
Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.
The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...
Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.
Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...
BQ 788 sodium salt
BQ 788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM) without significant activity on ETA receptor (IC50= 1300 nM).
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
Enrasentan, an indene derivative, has been found to be an endothelin receptor antagonist that was once studied in reperfusion injury and heart failure therapy.
IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.
Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...
atrasentan hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective anta...
Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hyperten...